Colicins are divided into two groups according t o the proteins required for their import into sensitive bacteria. The To1 and TonB pathways are involved in import of group A and group B colicins respectively. Because previous analyses have shown that colicin E l and colicin A (two group A colicins) interact in witro with the C-terminal domain of TolA (TolAlll) while colicin B (group B colicin) does not, attention was focused on these interactions with purified proteins.
INTRODUCTION
The To1 and TonB systems are involved in macromolecule import into Escherichia coli. Colicins and phage DNA have parasitized these protein complexes to penetrate into bacterial cells. In order to reach their cellular targets, colicins follow a three-step process. First, they bind to bacterial receptors; second, they translocate through the outer membrane; and third, they act either by forming a pore into the inner membrane or by exerting nuclease activity in the cell cytoplasm (for reviews see James et al., 1996; Lazdunski, 1995) . The TonB system is required for active transport of vitamin B,, and siderophores (Postle, 1993) , while the function of the To1 system is not yet understood, although it is required for the integrity of the cell envelope (Webster, 1991 ; Fognini-Lefkbvre et al., 1987; Lazzaroni & Portalier, 1992) . The TolA/B/Q/R/Pal and Orf2 proteins form the To1 system. The topologies of the inner-membrane-anchored TolA, TolQ and TolR proteins have been determined (Levengood & Webster, Abbreviation : SPR, surface plasmon resonance. Kampfenkel & Braun, 1993; Vianney et al., 1994; Miiller et al., 1993) . TolB and Orf2 have been found to be periplasmic proteins (Isnard et al., 1994; Vianney et al., 1996) . TolA, TolQ and TolR form an innermembrane Tol-protein complex, with the membrane domain of TolA interacting with TolQ and TolR (Derouiche et al., 1995) , while the membrane anchor of TolR was shown to interact with the third membrane segment of TolQ (Lazzaroni et al., 1995) . An outermembrane protein complex consisting of the periplasmic TolB protein and the lipoprotein Pal was also found (Bouveret et al., 1995) . Furthermore, cell-fractionation experiments have revealed that TolQ, -R, -A and -B form a protein complex of defined stoichiometry (Guihard et al., 1994) . TolA has been described as a three-domain protein (Levengood et al., 1991) , corresponding to a membrane anchor, a central domain and a C-terminal domain (domains I, I1 and 111, respectively) . In uitro, the TolA central domain (domain 11) interacts with outer-membrane trimeric porins and its function has been suggested to be related to the assembly process of outer-membrane porins requiring LPS (Derouiche et al., 1996) . When expressed and exported to the periplasm of wild-type cells, TolA 
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METHODS
Plasmid constructs. Plasmid pAR3 (Perez-Perez & Gutierrez, 1995) contains the chloramphenicol-resistance gene and ori from pACY184 with the araC gene and the araB promoter followed by the multiple cloning site from pAral2 (Cagnon et al., 1991) . An additional transcriptional terminator formed by an 81 bp DNA fragment from the crystal protein of Bacillus thuringiensis was inserted into the BglII restriction site, giving plasmid pART3 (J. Gutierrez, unpublished).
First, we inserted into the unique PstI site of pART3 a synthetic DNA fragment (5'-CATCATCATCATCATCACC GCATGCAAGCGGCCGCAAGGCCT-3') encoding six histidines, giving vector pARTHis. The six histidine codons are followed by three unique restriction sites, SphI, Not1 (or EagI) and StuI (underlined).
The plasmids encoding the TolA domain 11-111 and domain I11 were obtained by inserting the 1146 bp SphI-HpaI and the 447 bp EagI-HpaI DNA fragments of pTPS306 (Sun & Webster, 1986) into pARTHis digested by SphI-StuI and EagI-StuI, respectively. The plasmid encoding TolAII was obtained in two steps. First, the unique EspI site of pART3 was destroyed after being filled with Klenow polymerase and ligated. The SphI-HpaI DNA fragment encoding TolAII-I11 was inserted into this plasmid. Then, a synthetic DNA fragment containing two stop codons (Y-TAAGAGATCTG-TAATGAACCATGGAA-3') was inserted into the unique EspI site of the t ol AZZ-ZZZ gene. These three plasmids were called p ARTolAII-111, p ARTolAIII and pARTolAI1.
Plasmid pHS was obtained from plasmid pBRElSX in which two restriction sites were introduced between the three domains of the colicin E l gene (Frenette et al., 1991) . The SpeI-APII DNA fragment was deleted and thus plasmid pHS encodes the N-terminal domain of colicin El (HS domain).
Purification of TolA derivatives and N-terminal domains of colicins A and E l . The plasmids encoding TolAII-I11 and TolAIII were transformed into the recipient MC1061 cells (Cagnon et al., 1991) . TolAII, which was poorly induced in MC1061 (this might be due to the EspI mutation in the araC gene) , was expressed in C600 cells. Briefly, cultures were grown in LB (containing 30 pg chloramphenicol ml-l) to OD,,, 1.0. TolA expression was induced with 0 5 mg arabinose ml-l for 2 h. Cells were collected by centrifugation, lysed and further sonicated. After centrifugation at 100000 g, supernatants were directly incubated with nickel or cobalt beads (Nb or Cb, respectively) for 1 h. All buffers used for purification with Nb (50 mM sodium phosphate pH 8.0, 300 mM NaCl, 0.5 mM PMSF) and Cb (20 mM Tris/HCl pH 8.0, 100 mM NaC1, 0.5 mM PMSF) are described by Qiagen (Quiaexpressionist) and Clontech (TALON metal affinity resin) , respectively. After washing, the TolA derivatives were eluted with between 50 and 150 mM imidazole buffer. After dialysis against 20 mM Tris/HCl pH 7.6,20 mM NaCl buffer, the second step of purification was carried out using Monos cation-exchange chromatography (Pharmacia). TolAII-I11 and TolAIII were eluted with between 0.1 and 0 3 M NaCl; cation-exchange chromatography was not performed for TolAII. AT1 and HS (N-terminal domains of colicins A and El, respectively) were purified from C600 cell supernatants after induction with mitomycin C. Briefly, after ammonium sulphate precipitation and dialysis against 50 mM phosphate buffer pH68, the N-terminal domains were purified by Monos chromatography as described for AT1 by Knibiehler et af. (1989) . Colicin A was purified as described by Baty et al. (1987) , while colicin El was a gift from W. A. Cramer (Purdue University, Ind., USA).
Amino acid compositions and N-terminal protein sequences.
Amino acid composition determinations performed on purified TolA derivatives, AT1 and HS proteins gave the expected ratios. From two amino acid compositions, the E ,~, values of TolAII-I11 and TolAIII were calculated to be 10300 and 6900 M-' cm-', respectively. N-terminal sequences of TolAIII and TolAII-I11 were checked and the results indicated that the N-terminal formylmethionine was removed. Since TolAII does not have many aromatic residues (no W, no Y and only one F residue), the &280 was not estimated.
Western blot analysis.
Overlay techniques have been previously described by Bknkdetti et al. (1991) . Briefly, TolA derivatives were heat-denatured with reducing agent in sample buffer before SDS-PAGE. After Western blotting of purified TolA derivatives, colicins were first incubated and immunodetected with their respective antibodies : monoclonal antibodies (mAbs) l C l l or 3D6 for colicin A (Cavard et al., 1986) , or the polyclonal antibody (pAb) raised against the N-terminal domain of colicin El (anti-HS antibody), or a pAb raised against colicin El or colicin B. Then, immunodetection of colicin at the corresponding migration mobility of the TolA derivative confirmed that colicin interacted with purified TolA domains. The antibodies were previously checked for the absence of cross-reactivity with TolA.
SDSPAGE shift assay. Protein complexes formed between
TolA derivatives and either colicin A (or ATl), or colicin El (or HS) were analysed by SDS-PAGE. The incubations (15 to 30 min) of TolA with colicin derivatives were carried out in 10 mM Tris/HCl pH 8.0, 100mM NaCl. Samples were directly applied with the addition of sample buffer (devoid of SDS, dye and reducing agent) on SDS-PAGE without any denaturing step and the electrophoreses run between 10 and 20 V cm-'. Purified proteins were analysed by Coomassie blue staining.
Peptide synthesis. Two peptides encompassing the putative N-terminal ' TolA box' sequence (Pilsl & Braun, 1995) were synthesized and further purified by reverse-phase chromatography to perform competition-binding to TolAIII with their respective N-terminal domains. The sequences correspond to NH,-G,,TPDGSGSGGG-COOH (G11G) and NH,-G,K-GDGTGWSSE-COOH (G11E). The putative TolA boxes are underlined, with the position of the first residue of colicin El and colicin A, respectively, indicated.
SPR (BIAcore).
The BIAcore system and reagents for interaction analysis including CM5 sensor chips, surfactant P20, N-hydroxysuccinimide (NHS) and N-ethyl-N'-(3-dimethylaminopropy1)carbodiimide hydrochloride (EDC) were obtained from Pharmacia Biosensor. Interaction analysis was performed in 10 mM HEPES, 150 mM NaC1,3.4 mM EDTA, 0.005 YO surfactant P20, pH 7.4 (HBS buffer). TolA derivatives diluted (about 10-fold) to 100 pM in 10 mM acetate pH 5.0 were immobilized on CMS sensor chips through primary amino groups according to the standard EDC/NHS procedure (Johnsson 8c Lofis, 1991). Concentrations ranging from 0-2 to 2 pM of colicins A, AT1, colicin E l and HS in HBS buffer were used. To suppress the interaction observed when colicins A and E l were injected onto the dextran matrix of the sensor chip, the colicins were diluted in HBS with 1 mg carboxymethyldextran ml-l (Fluka). Colicin B was used as a negative control. Regeneration 
RESULTS
Plasmid constructs and protein purification
Large amounts of TolA derivatives were obtained using the tightly regulated araB promoter from pART3 (see Methods). This plasmid contained the araC gene encoding the arabinose repressor acting on the araB promoter. To facilitate protein purification, a synthetic DNA fragment encoding an N-terminal six-histidine tagging sequence was added. Three plasmids, pARTolAI1, pARTolAIII and pARTolAI1-111, were constructed which expressed TolAII, TolAIII and TolAII-I11 proteins corresponding to 236 residues of the central domain, 132 residues of the C-terminal domain and 355 residues of the two soluble domains, respectively (Fig. 1) . Soluble TolA derivatives were overproduced after 2 h of arabinose induction and were recovered after sonication of the cell pellet and ultracentrifugation. The first step of purification was obtained by chelating the histidine-tagged recombinant proteins on NTAnickel beads (Nb) and eluting them by a batch procedure using increasing concentrations of imidazole buffer. By this approach, in addition to TolA derivatives, a protein was eluted between 20 and 40 mM imidazole. The Nterminal sequence of this protein was determined after being transferred onto a PVDF membrane. The first 10 residues, MTIFDNYEVN, were found to correspond to E . coli arabinose isomerase (which contains 21 histidines among the 500 residues). Cationic exchange chromatography was performed for TolAIII and TolAII-I11 purification to eliminate contaminants. TolA derivatives, colicins A and E l and their N-terminal domains are shown in Fig. 2 and represent at least 90% purified proteins.
Overlay immunodetection of colicin binding to Western-blotted TolA derivatives
The antibodies were checked for their cross-reactivity with TolA derivatives before overlay immunodetection. A low background interaction was observed using the anti-HS antibody due to cross-reaction with TolA domain 11; all the other antibodies, including the anticolicin E l antibody, did not cross-react with TolA. The overlay assays were performed according to the immunodetection of bound colicin on Western-blotted TolA domains. By this approach using anti-colicin E l and anti-HS antibodies colicin E l was clearly detected on Western-blotted TolAIII while its N-terminal domain (HS) was poorly immunodetected. T o avoid any steric hindrance that might occur between the antibody recognition sequence and the region interacting with TolAIII, we used the hybrid colicin ElAA, which comprises the N-terminal domain of colicin E l (identical to that of the HS protein) and the central and C-terminal domain of colicin A (Frenette et al., 1991) . Its binding to (Table 1) .
Gel shift assays of colicins binding to TolA
When colicin A and AT1 were incubated with TolAII-I11 or TolAIII without denaturing agent and further analysed by SDS-PAGE shift assay, high-molecular-mass bands appeared after Coomassie blue staining (Fig. 3) . Western blot immunodetections indicated that these bands corresponded to complexes formed by TolA and colicin A (not shown). According to the molecular masses of these complexes, they might correspond to a heterodimer formed by colicin A (or AT1) and TolAIII (or TolAII-111). Upon heat denaturation the monomeric form of each protein was recovered. No protein complex was observed between TolAII and colicin A, and no TolA derivative interacted with colicin E l and HS to form a band shift under the same conditions (Fig. 3) . As a negative control, when colicin B or the C-terminal domain of colicin A was used, no complex was detected (not shown).
Estimation of the kinetic values of colicin binding to immobilized TolAlll by SPR measurements
The biosensor monitors interactions between pairs of molecules when one partner (the ligand) is immobilized type TolAon the surface of the sensor and the other (the analyte) is in solution. TolAII-I11 and TolAIII were immobilized on CM5 sensor chips through primary amino groups. Their interactions with colicins A, E l and their Nterminal domains were clearly detected, whereas no interaction was observed using colicin B, the C-terminal domain of colicin A, and the purified colicin A derivative deleted of residues 32 to 172 (Bknkdetti et al., 1991) (not shown). BIAcore experiments clearly showed the interaction between HS or AT1 with TolAII-I11 and TolAIII domains, while no interaction occurred with TolAII. Fig. 4 shows the superimposition of two sensorgrams obtained with the N-terminal domains of colicins A (AT1) and E l (HS) injected at the same concentration onto immobilized TolAIII. Some differences between HS and AT1 on TolAIII were observed, with a stronger association and higher dissociation rate for HS. T o characterize the colicin-TolA interaction, we also measured kinetic constants. Under normal experimental conditions, and with a homogeneous binding partner, the association is expected to be pseudo-first order, as the analyte is continuously re- HS, respectively) were determined by an average of two amino acid compositions per protein. The homogeneity of each interactant was checked by SDS-PAGE (Fig. 2) and was at least 90%. The analytical centrifugation experiments indicated the oligomeric state of the proteins. TolAIII and TolAII were monomeric in solution (data not shown), as was colicin A (Cavard et al., 1988) and its N-terminal domain (Knibiehler et al., 1989) .
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Two sets of four sensorgrams for each colicin fragment (concentrations ranging from 0.2 to 2.0 pM) were analysed using a pseudo-first-order kinetic model (A + BwAB). The experimental sensorgrams were poorly described by that homogeneous model, as indicated by the large magnitude of x2 ( > > 10) associated with the best-fit description obtained by nonlinear regression analysis. Instead, a second exponential term in the integrated rate equation is required to describe the binding data more accurately, which involves a second, slower-binding phase. Apparent kinetic constants values were deduced using a more complex model:
A + B, + B,@AB, + AB,, where the response upon time is described by two exponential terms. In this case the quality of the fit was better, as indicated by the decreased magnitude of x2 values (below 5 for HS and colicin E l and generally below 10 for colicins A and AT1).
Apparent values of k, and k d estimated for AT1 and HS on immobilized TolAIII and TolAII-I11 are shown in Table 2 . The Kdi was calculated as the ratio kdi/kai. Kd1 Table 2 A putative TolA box formed with the pentapeptide DGSG(S/W) was suggested for the colicins El, E2 and E3 as well as for colicin A (sequence DGTGW) (Pilsl & Braun, 1995) . We checked if such a peptide might compete with the interaction of the N-terminal domain of colicin A and E l (fixed concentration of 0.2 pM) with immobilized TolAIII. Two 11-mer peptides containing the specific pentapeptide and the surrounding sequence of colicin A and E l were synthesized (see Methods). Using 1,10,100 and 1000 molar ratio of G l l G peptide to HS protein, no decrease in the signal response was measured, compared to the results obtained in the absence of peptide. This result was the same when using an increasing ratio of G l l E peptide with AT1 protein.
According to the RU signal, which is related to the molecular mass of the interactant, we might expect a decrease in the RU signal if the peptide interacted with TolAIII. Our data indicated that no competition occurred with the two peptides containing the putative TolA boxes of colicins A and El.
DISCUSSION
This study describes the purification of TolA soluble derivatives with six-histidine tagging extensions, and their interaction with the translocation domain of colicins A and El. We have previously shown, using crude cell extracts and overlay immunodetections, that TolAIII interacts with colicin A and E l and that this interaction might be relevant to the in uiuo translocation of colicins (BCnidetti et al., 1991) . Here, with purified proteins, different approaches were used to analyse these interactions in uitro.
The six-histidine tagging system and the tightly regulated arabinose promoter-operator vector were useful for the purification of TolA derivatives since initial attempts of TolA purification using the T7 expression system without any tagging yielded very low amounts of soluble TolA derivatives (not shown). The first step in affinity purification was performed by a batch procedure (using either Nb or Cb), then a second step of purification by Monos chromatography was necessary to remove contaminants. Using this approach, the arabinose isomerase was purified after elution with a low imidazole concentration. Optimization of production expression and the purification procedures is now in progress.
For the first time, we have demonstrated that the Nterminal domain of colicin E l (HS), like that of colicin A (ATl), can interact with the C-terminal domain of TolA (TolAIII) . Overlay analyses were performed using various antibodies. Because we observed that the antibody directed against the N-terminal domain of colicin E l (HS) cross-reacted with TolAII, we checked for the homology of HS against a protein database by using the NCBI BLAST network service. A sequence of 123 residues within TolAII protein was found with 37% identity to that of HS (while no significant homology was found with ATl), which might explain the cross-reactivity of this antibody. The homologous regions corresponded to residue 43 to 156 and 113 to 226 of colicin E l and TolA, respectively. The overlay assay using HS or the hybrid colicin E l AA followed by immunodetection using the anti-HS antibody (which does not cross-react with TolAIII) or the monoclonal antibody directed against colicin A demonstrated that TolAIII-HS interaction did occur. Mobility shift assays using SDS-PAGE confirmed the interaction of AT1 with TolAIII when the incubation was performed in the absence of SDS. According to the migration mobilities, the TolA-colicin complexes corresponded to dimers. However, by the same approach (SDS-PAGE followed by Coomassie blue staining), no complex was detected using colicin E l or HS. This might indicate that the colicin El-TolA interaction dissociated more rapidly during electrophoreses in the presence of SDS.
The last set of in uitro analyses was performed using SPR techniques. The first attempts at immobilization were obtained by amine coupling. Since the proteins contain numerous basic residues their coupling should generate some heterogeneity of presentation of the proteins on the chip. Another procedure using NTA coupling and further Ni2+-chelating (Gershon & Khilko, 1995) was performed but did not work for the TolAimmobilization step, although the histidine extension was still detected by Western blotting. This can probably be explained by a faster dissociation of the chelated TolA under SPR conditions. However, by the amine coupling approach, the qualitative results indicating that the N-terminal domains of colicin A and E l specifically interacted with TolAIII were confirmed. We also checked that TolAIII interacted with immobilized colicins A and El. Quantitative data obtained with the BIAcore enabled us to estimate only the apparent kinetic parameters, since sensorgram interpretations deviate from pseudo-first-order kinetics. Several factors are likely to cause this kind of deviation, such as heterogeneity of ligand sites within the matrix, restricted access of the analyte to the ligand sites because of mass transport limitation or parking problems resulting from possible masking of potential sites by bound analytes (O'Shannessy & Winzor, 1996) . The most common source, which was probably responsible in our experiments, is the heterogeneity of immobilized ligand sites, as the amine coupling chemistry used does not provide homogeneous presentation of the TolA molecules. Under these conditions, and knowing that the TolAIII protein was monomeric in solution and that the protein complex might correspond to a dimer (see above), the dissociation constants were found to be between 0.2 and 0.6 pM for the N-terminal domains of colicins A and E l binding to immobilized TolAIII. Elementary tests for self-consistency of kinetic analysis obtained with biosensor instruments have been recently proposed but they are inappropriate in this analysis as they assumed a Binding of colicins A and E l to purified TolA domains simple binding model to be valid (Schuck & Minton, 1996) . However, due to the relative deviation values, no significant differences were found between TolAIII and TolAII-111. On the other hand, competition experiments using two peptides containing the putative TolA boxes located within the N-terminal sequences of colicins A and E l (Pilsl & Braun, 1995) were checked in competition assays with their respective colicin. The peptide containing residues 8 to 19 of colicin A did not interfere with AT1 binding on TolAIII. This is in accordance with the result obtained by Bknddetti et al. (1991) showing that the colicin A derivative deleted of residues 32 to 172 did not interact with TolA in overlay experiments, and suggests that residues 8 to 19 of colicin A do not correspond to a TolA box. However, we did not find any competition with the peptide of colicin E l on HS binding either. Because we do not have a positive control, such experiments using SPR will be useful to check for a peptide sequence inhibiting colicin interaction to give a clear conclusion. New experiments using the isothermal titration calorimetry (ITC) technique have been described to analyse the interactions between colicin N, its OmpF receptor and other porins (Evans et al., 1996) . Such experiments using the ITC or SPR techniques with colicins, their receptors and To1
proteins might provide useful thermodynamic and kinetic information about the translocation step of colicins through the outer membrane.
